Evidence map›Paper›PMID 32556890›Full record

ArticlePathology oncology research : POR2020

Association of KLK3, VAMP8 and MDM4 Genetic Variants within microRNA Binding Sites with Prostate Cancer: Evidence from Serbian Population.

Nevena Kotarac, Zorana Dobrijevic, Suzana Matijasevic, Dusanka Savic-Pavicevic, Goran Brajuskovic

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nevena KotaracCentre for Human Molecular Genetics, Faculty of Biology, University of Belgrade, Belgrade, Serbia.
Zorana DobrijevicCentre for Human Molecular Genetics, Faculty of Biology, University of Belgrade, Belgrade, Serbia.
Suzana MatijasevicCentre for Human Molecular Genetics, Faculty of Biology, University of Belgrade, Belgrade, Serbia.
Dusanka Savic-PavicevicCentre for Human Molecular Genetics, Faculty of Biology, University of Belgrade, Belgrade, Serbia.
Goran BrajuskovicCentre for Human Molecular Genetics, Faculty of Biology, University of Belgrade, Belgrade, Serbia. brajuskovic@bio.bg.ac.rs.ORCID https://orcid.org/0000-0002-3935-6755
University of Belgrade · RS

Funding

Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja 173016
6 · The paper itself

Abstract

A growing number of studies have suggested that genetic variants affecting the micro-RNA- binding mechanisms (miRSNPs) constitute a promising novel class of biomarkers for prostate cancer (PCa) biology. Among the most extensively studied miRSNPs in the context of cancer is the variation rs4245739 in the MDM4 gene, while a recent large-scale analysis revealed significant differences in genotype distributions between aggressive and non-aggressive disease for rs1058205 in KLK3 and rs1010 in VAMP8. In this study, we examined a total of 1083 subjects for these three variants using Taqman® SNP Genotyping Assays. Three hundred and fifty-five samples of peripheral blood were obtained from patients with PCa and 358 samples from patients with benign prostatic hyperplasia (BPH). The control group consisted of 370 healthy volunteers. Comparisons of genotype distributions among PCa and BPH patients, as well as between PCa patients and healthy controls, yielded no evidence of association between the analyzed genetic variants and the risk of developing PCa. However, all three tested genetic variants have shown the association with the parameters of PCa progression. For KLK3 variant rs1058205, minor allele C was found to associate with the lower serum PSA score in PCa patients (PSA > 20 ng/ml vs. PSA < 10 ng/ml comparison, Prec = 0.038; ORrec = 0.20, 95%CI 0.04-1.05). The obtained results point out the potential relevance of the tested genetic variants for the disease aggressiveness assessment.

Indexed as

AgedBinding SitesBiomarkers, TumorCell Cycle ProteinsGenetic Predisposition to DiseaseGenetic VariationHumansKallikreinsMaleMicroRNAsMiddle AgedProstate-Specific AntigenProstatic NeoplasmsProto-Oncogene ProteinsR-SNARE ProteinsSerbiaBiomarkers, TumorCell Cycle ProteinsKallikreinsKLK3 protein, humanMDM4 protein, humanMicroRNAsProstate-Specific AntigenProto-Oncogene ProteinsR-SNARE ProteinsVAMP8 protein, humanmiRSNPsProstate cancerrs1010rs1058205rs4245739

Identifiers

PMID32556890
OpenAlexW3036554706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.